Work

Phase 2 study of telomere-targeting agent THIO sequenced with cemiplimab in third-line immune checkpoint inhibitor–resistant advanced NSCLC: Evaluation of overall survival (OS).

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.8585

Authors: Tomasz Jankowski, Tibor Csőszi, Laszlo Urban, Tunde Nagy, Rodryg Ramlau, Maria Cholakova, Nataliya Chilingirova, Andrzej Mruk, Szabolcs Soter, Krassimir Dimitrov Koynov, Marek Kotlarski, Romina Girotti, Ilgen Mender, Marcel Mitsunaga, Oleg Tudos, Matthew Failor, Bin Yao, Vlad Vitoc, Sergei Gryaznov, Victor Zaporojan

Institutions: Medical University of Lublin, Poznan University of Medical Sciences, Országos Korányi Tbc és Pulmonológiai Intézet, Universidad Argentina de la Empresa

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410805461

Cites:

Cited by:

Related to: 10